Impact of Prior Chemotherapy (Chemo) on Progression-free Survival (PFS) in Patients (Pts) with Advanced, Nonfunctional Lung or Gastrointestinal (GI) Neuroendocrine Tumors (NET): A Secondary Analysis from the Phase 3 RADIANT-4 Study.
#1502
Introduction: In the phase 3 RADIANT-4 study, everolimus (EVE) improved PFS by 7.1 months (mo) compared to placebo (PBO; P<0.00001) in pts with advanced, progressive, nonfunctional NET of lung or GI tract.
Aim(s): To evaluate impact of prior chemo use on PFS in RADIANT-4.
Materials and methods: In RADIANT-4, pts were randomized (2:1) to EVE 10mg/d or PBO, both with best supportive care. A subgroup analysis of the RADIANT-4 study by prior chemo use is presented.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Pommier R
Authors: Pommier R, Strosberg J, Singh S, Wolin E, Yao J,
Keywords: Everolimus, nonfunctional NET, prior chemotherapy,
To read the full abstract, please log into your ENETS Member account.